Immunoassay Reagent Vitros® Anti-SARS-CoV-2 Total N Antibody For Vitros ECi / ECiQ / 3600 Immunodiagnostic Systems and the Vitros 5600 / XT 7600 Integrated Systems

USAMP#31952547SKU: 6199975Vitros®
wishlistAltwishlistAlt
Immunoassay Reagent Vitros® Anti-SARS-CoV-2 Total N Antibody For Vitros ECi / ECiQ / 3600 Immunodiagnostic Systems and the Vitros 5600 / XT 7600 Integrated Systems

Product Spotlight

  • The Vitros Anti-SARS-CoV-2 Total N Antibody test is only for use under the Food and Drug Administration's Emergency Use Authorization: https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/in-vitro-diagnostics-euas-serology-and-other-adaptive-immune-response-tests-sars-cov-2
  • Testing is limited to laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, that meet the requirements to perform moderate or high complexity tests
  • VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total N Antibody Reagent Pack when used in combination with the VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total N Antibody Calibrators is a chemiluminescent immunoassay test intended for the qualitative detection of total antibody (including IgG, IgA and IgM) to SARS-CoV-2 nucleocapsid protein in human serum and plasma (K2 -EDTA)
  • Laboratories within the United States and its territories are required to report all results to the appropriate public health authorities
  • The sensitivity of VITROS Anti-SARS-CoV-2 Total N Antibody test in early infection is unknown; negative results do not preclude acute SARS-CoV-2 infection; if acute infection is suspected, direct testing for SARS-CoV-2 is necessary
  • False positive results for VITROS Anti-SARS-CoV-2 Total N Antibody test may occur due to cross-reactivity from pre-existing antibodies or other possible causes
  • Negative results do not rule out SARS-CoV-2 infection, particularly in those who have been in contact with the virus
  • Positive results may be due to past or present infection with non-SARS-CoV-2 coronavirus strains, such as coronavirus HKU1, NL63, OC43, or 229E
  • Reagent Pack contains: 100 coated wells (streptavidin, bacterial; binds ≥ 3 ng biotin per well; recombinant SARS-CoV-2 nucleocapsid antigen 14 ng/well), 6.0 mL assay reagent (buffer with bovine protein stabilizers and antimicrobial agent), 16.2 mL conjugate reagent (HRP-recombinant SARS-CoV-2 nucleocapsid antigen) in buffer with bovine protein stabilizers and antimicrobial agent